79,625 results match your criteria Systemic Lupus Erythematosus


Mannose Binding Lectin Levels and its Association with Systemic Lupus Erythematosus Disease Severity: An Indian Report.

J Assoc Physicians India 2022 May;70(5):11-12

Department of Clinical & Experimental Immunology, National Institute of Immunohaematology, Indian Council of Medical Research, King Edward Memorial Hospital, Mumbai, Maharashtra Corresponding Author.

Background: Dysregulated serum levels of Mannan binding lectin (MBL) has a probable role in Systemic Lupus Erythematosus (SLE) pathogenesis.

Objective: To evaluate the association between serum MBL levels in SLE patients from western India with the severity of disease Methods: SLE patients (n=70) from Western India were included. Based on MBL levels, patients were classified into four categories, viz. Read More

View Article and Full-Text PDF

Risk Factors and Outcomes for COVID-19 in Autoimmune Inflammatory Diseases during the SARS-CoV-2 Pandemic: A Comparative Study.

Isr Med Assoc J 2022 May;24(5):299-305

Department of Postgraduate Studies, Faculty of Medicine, National University Autonomous of Mexico, México City, México.

Background: Patients with autoimmune disease (AID) and coronavirus disease 2019 (COVID-19) could have higher mortality due to the co-morbidity and the use of immunosuppressive therapy.

Objectives: To analyze the risk factors and outcomes of patients with AID and COVID-19 versus a control group.

Methods: A prospective cohort study included patients with and without AID and COVID-19. Read More

View Article and Full-Text PDF

Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review.

Rheumatol Ther 2022 May 21. Epub 2022 May 21.

GlaxoSmithKline, Research Triangle Park, NC, USA.

Introduction: Belimumab is a recombinant human monoclonal antibody that binds to soluble B-lymphocyte stimulator and inhibits its biological activity. Since receiving approvals for the treatment of systemic lupus erythematosus (SLE), several observational studies have investigated the effectiveness of belimumab in the real-world setting. This study reports a systematic review and meta-analysis of the literature to evaluate the real-world effectiveness of belimumab for the treatment of SLE. Read More

View Article and Full-Text PDF

Inflammaging and Frailty in Immune-Mediated Rheumatic Diseases: How to Address and Score the Issue.

Clin Rev Allergy Immunol 2022 May 21. Epub 2022 May 21.

Rheumatology Clinic, Università Politecnica Delle Marche, Carlo Urbani" Hospital, Via Aldo Moro, 25, 60035, Jesi, Ancona, Italy.

Frailty is a new concept in rheumatology that can help identify people more likely to have less favorable outcomes. Sarcopenia and inflammaging can be regarded as the biological foundations of physical frailty. Frailty is becoming more widely accepted as an indicator of ageing and is linked to an increased risk of negative outcomes such as falls, injuries, and mortality. Read More

View Article and Full-Text PDF

Lupus nephritis - An update on disparities affecting african americans.

J Natl Med Assoc 2022 May 17. Epub 2022 May 17.

Department of Kidney Medicine, Cleveland Clinic Florida, Weston, FL, United States. Electronic address:

Lupus Nephritis is a complex clinical manifestation of systemic lupus erythematosus (SLE) associated with significant morbidity and mortality. It disproportionately affects minorities, especially African Americans (AA) with higher rates of progression to end stage kidney disease. Several factors are implicated including genetic predisposition to both SLE and chronic kidney disease, social determinants of health such as income inequality, education disparities, social isolation/lack of support, health care access and affordability. Read More

View Article and Full-Text PDF

A case of recurrent IgG4-related disease successfully treated with belimumab after remission of systemic lupus erythematosus.

Rheumatology (Oxford) 2022 May 20. Epub 2022 May 20.

Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

View Article and Full-Text PDF

Successful remission with tofacitinib in a patient with refractory bullous systemic lupus erythematosus.

Rheumatology (Oxford) 2022 May 20. Epub 2022 May 20.

Department of Rheumatology and Immunology, Peking University International Hospital, Beijing, 102206, China.

View Article and Full-Text PDF

Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications.

Autoimmun Rev 2022 May 17:103114. Epub 2022 May 17.

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

From the introduction of hyperferritinemic syndrome concept, a growing body of evidence has suggested the role of ferritin as a pathogenic mediator and a relevant clinical feature in the management of patients with inflammatory diseases. From a pathogenic point of view, ferritin may directly stimulate the aberrant immune response by triggering the production of pro-inflammatory mediators in inducing a vicious pathogenic loop and contributing to the occurrence of cytokine storm syndrome. The latter has been recently defined as a clinical picture characterised by elevated circulating cytokine levels, acute systemic inflammatory symptoms, and secondary organ dysfunction beyond that which could be attributed to a normal response to a pathogen It is noteworthy that the occurrence of hyperferritinemia may be correlated with the development of the cytokine storm syndrome in the context of an inflammatory disease. Read More

View Article and Full-Text PDF

Prominent B cell signature differentiates discoid from subacute cutaneous lupus erythematosus.

J Invest Dermatol 2022 May 17. Epub 2022 May 17.

Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA; Department of Medicine, Division of Allergy/Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA. Electronic address:

While B cells account for a significant proportion of the lymphocytic infiltrate in discoid lupus erythematosus (DLE), their contribution to pathogenesis is unknown. In this study, we compare the immune landscape of 17 subjects with DLE to 21 subjects with subacute cutaneous lupus erythematosus (SCLE) using transcriptomic and histologic analyses of lesional skin. A few of the subjects (3/17 DLE, 5/21 SCLE) had concomitant systemic lupus erythematosus (SLE). Read More

View Article and Full-Text PDF

Simultaneous electrochemical immunosensing of relevant cytokines to diagnose and track cancer and autoimmune diseases.

Bioelectrochemistry 2022 May 14;146:108157. Epub 2022 May 14.

Department of Analytical Chemistry, Faculty of Chemistry, Complutense University of Madrid, 28040 Madrid, Spain.

This work reports the first dual magnetic beads (MBs) assisted immunoplatform for the simultaneous determination of BAFF (B cell activation factor) and APRIL (a proliferation-induced ligand), two cytokines related to immunity and tumour invasion, growth and metastasis. The electrochemical immunoplatform involves sandwich-type immunoassays implemented on magnetic microparticles functionalized with neutravidin (NA-MBs) or carboxylic groups (HOOC-MBs), and amperometric detection (E =  - 0.20 V vs. Read More

View Article and Full-Text PDF

Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studies.

EBioMedicine 2022 May 17;80:104055. Epub 2022 May 17.

Department of Orthopaedics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China; Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. Electronic address:

Background: Emerging evidence suggests that dysbiosis in gut microbiota may contribute to the occurrence or development of several rheumatic diseases. Since gut microbiota dysbiosis is potentially modifiable, it has been postulated to be a promising preventive or therapeutic target for rheumatic diseases. However, the current understanding on the potential associations between gut microbiota and rheumatic diseases is still inadequate. Read More

View Article and Full-Text PDF

Ghrelin is associated with anti-mullerian hormone levels in Chinese systemic lupus erythematosus.

Am J Reprod Immunol 2022 May 20. Epub 2022 May 20.

Department of Rheumatology and Immunology, Tangdu hospital of The Air, Force Medical University, 569 of Xinsi Road, Xi'an, China.

Problem: Ghrelin has been though of as a potential link between energy homeostasis and fertility. The aim of this study was to evaluate levels of ghrelin in obese and non-obese systemic lupus erythematosus (SLE) patients, and to reveal a possible association between ghrelin and Anti-Mullerian hormone (AMH) in SLE patients.

Method Of Study: One hundred SLE patients (50 obese and 50 non-obese subjects) at childbearing age and 100 age-matched healthy controls (50 obese and 50 non-obese subjects) were included. Read More

View Article and Full-Text PDF

Elevated serum cholesterol levels are associated with proteinuria over 0.5 g/day in premenopausal women with systemic lupus erythematosus.

Int J Immunopathol Pharmacol 2022 Jan-Dec;36:3946320221101287

Department of Rheumatology, School of Medicine, South China University of Technology, 74668Guangzhou First People's Hospital, Guangzhou, China.

Systemic lupus erythematosus (SLE) commonly occurs in premenopausal women and is associated with elevated estrogen levels. Patients with SLE may have abnormal serum triglyceride (TG) levels, and lipid reportedly promotes kidney damage in patients with nephrosis. Since estrogen regulates lipid levels, we investigated the serum lipid levels of premenopausal women with SLE and their relationship with proteinuria. Read More

View Article and Full-Text PDF

Neurological complications in systemic inflammatory diseases.

Curr Rheumatol Rev 2022 May 18. Epub 2022 May 18.

Department of neurology. Hospital Universitario de Torrejón, Spain.

Systemic inflammatory diseases could produce neurologic complications, and they are frequently incorporated in the differential diagnosis of neurological symptoms. There are well-established criteria to meet the diagnosis of neurologic manifestations of these systemic diseases. However, the range of clinical presentations varies in each condition, and the prevalence of these complications differs between studies. Read More

View Article and Full-Text PDF

Epigenetic Regulation of IFI44L Expression in Monocytes Affects the Functions of Monocyte-Derived Dendritic Cells in Systemic Lupus Erythematosus.

J Immunol Res 2022 10;2022:4053038. Epub 2022 May 10.

Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital of Central South University, Changsha, China.

Background: Interferon-inducible 44 like (IFI44L) is a newly discovered interferon-induced gene and has been reported to overexpress in systemic lupus erythematosus (SLE). However, little is known about the mechanism and function of IFI44L overexpression in SLE. In this study, we aimed to investigate the epigenetic mechanism of IFI44L overexpression in SLE monocyte and its potential functions contributing to the pathogenesis of SLE. Read More

View Article and Full-Text PDF

Two complications in patients with systemic lupus erythematosus: lupus cystitis and lupus enteritis.

Arch Med Sci 2022 20;18(3):822-824. Epub 2022 Apr 20.

Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.

View Article and Full-Text PDF

Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus.

Wellcome Open Res 2021 12;6:149. Epub 2022 May 12.

JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

The characterisation of the peripheral immune system in the autoimmune disease systemic lupus erythematosus (SLE) at the single-cell level has been limited by the reduced sensitivity of current whole-transcriptomic technologies. Here we employ a targeted single-cell multi-omics approach, combining protein and mRNA quantification, to generate a high-resolution map of the T lymphocyte and natural killer (NK) cell populations in blood from SLE patients. We designed a custom panel to quantify the transcription of 534 genes in parallel with the expression of 51 surface protein targets using the BD Rhapsody AbSeq single-cell system. Read More

View Article and Full-Text PDF

Characteristics of childhood-onset systemic lupus erythematosus in pregnancy and its association with pregnancy outcomes: a retrospective comparative cohort study.

Reprod Biol Endocrinol 2022 May 19;20(1):78. Epub 2022 May 19.

Department of Epidemiology, School of Public Health, Southern Medical University, No.1846, North of Guangzhou Avenue, Guangzhou, 510515, Guangdong, China.

Background: Disease situations are more aggressive in patients with childhood-onset systemic lupus erythematosus (cSLE) than in those with adult-onset SLE (aSLE). However, information on pregnant women with cSLE and its association with pregnancy outcomes is limited. This study aimed to compare pregnancies in patients with cSLE vs. Read More

View Article and Full-Text PDF

High risk of depression, anxiety, and an unfavorable complex comorbidity profile is associated with SLE: a nationwide patient-level study.

Arthritis Res Ther 2022 May 19;24(1):116. Epub 2022 May 19.

Department of Rheumatology and Clinical Immunology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.

Objectives: The aim of this national population-based, retrospective database study is to compare the comorbidity profiles of systemic lupus erythematosus (SLE) patients and general population controls matched for age, gender, and region and assess the risk of depression or anxiety when controlled for age, gender and adjusted for the Charlson Comorbidity Index (CCI).

Methods: Claims data of 1051 patients diagnosed with SLE (full population between January 01, 2011, and December 31, 2014) from the Hungarian National Health Insurance Fund have been analyzed against matched controls (1:5 ratio) with a follow-up of 30 months. The first record of SLE diagnosis was considered the diagnosis date. Read More

View Article and Full-Text PDF

Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematous in monogenic lupus.

Clin Rheumatol 2022 May 19. Epub 2022 May 19.

Pediatric Rheumatology, King Faisal Specialist Hospital and Research Center, College of Medicine, Alfaisal University, Po Box 3354, Riyadh, 11211, Saudi Arabia.

Objective: To evaluate the application of the EULAR/ACR-2019 criteria to monogenic lupus patients and compare its performance against the SLICC-2012 criteria.

Methods: In a multicenter retrospective cohort study, consecutive patients with monogenic lupus from three tertiary lupus clinics were enrolled. The diagnosis of monogenic lupus was based on the expert physician's opinion or fulfilling the SLICC-2012 criteria. Read More

View Article and Full-Text PDF

Naturally Occurring Anti-Idiotypic Antibodies Portray a Largely Private Repertoire in Immune-Mediated Thrombotic Thrombocytopenic Purpura.

J Immunol 2022 May 18. Epub 2022 May 18.

Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; and Department for BioMedical Research, University of Bern, Bern, Switzerland

Rare immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening disease resulting from a severe autoantibody-mediated ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motifs, member 13) deficiency. Acute iTTP episodes are medical emergencies, but when treated appropriately >95% of patients survive. However, at least half of survivors will eventually experience a relapse. Read More

View Article and Full-Text PDF

Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.

Hum Vaccin Immunother 2022 May 19:2072143. Epub 2022 May 19.

Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.

In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human monoclonal IgG1λ antibody neutralizing soluble B cell activating factor, was approved more than ten years ago as add-on therapy in adults and pediatric patients with a highly active, autoantibody-positive disease despite standard of care (SoC). Read More

View Article and Full-Text PDF

Nanotechnology applications in rheumatology.

Rheumatol Int 2022 May 19. Epub 2022 May 19.

Southport and Ormskirk Hospital NHS Trust, Southport, PR8 6PN, United Kingdom.

Nanomedicine (NM) is the medical use of nanotechnology (NT). NT is the study and control of nanoscale structures (between approximately 1 and 100 nm). Nanomaterials are created by manipulating atoms and molecules at the nanoscale, resulting in novel physical and chemical properties. Read More

View Article and Full-Text PDF

Jagged Ends on Multinucleosomal Cell-Free DNA Serve as a Biomarker for Nuclease Activity and Systemic Lupus Erythematosus.

Clin Chem 2022 May 19. Epub 2022 May 19.

Centre for Novostics, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong SAR, China.

Background: Jagged ends of plasma DNA are a recently recognized class of fragmentomic markers for cell-free DNA, reflecting the activity of nucleases. A number of recent studies have also highlighted the importance of jagged ends in the context of pregnancy and oncology. However, knowledge regarding the generation of jagged ends is incomplete. Read More

View Article and Full-Text PDF

Comparative efficacy and safety of mizoribine and mycophenolate mofetil for treating systemic lupus erythematosus: a retrospective cohort study.

Ther Adv Musculoskelet Dis 2022 13;14:1759720X221096367. Epub 2022 May 13.

Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Background: Mizoribine (MZR) is an immunosuppressive agent that selectively inhibits inosine monophosphate dehydrogenase; its actions are considerably similar to those of mycophenolate mofetil (MMF). This study aimed to clarify whether MZR can be a good treatment option for systemic lupus erythematosus (SLE) and to compare the efficacy and safety of MZR and MMF in patients with active SLE.

Methods: We retrospectively compared the efficacy, continuation rate, and safety of MZR (52 patients) and MMF (31 patients) after adjusting for stabilized inverse probability of treatment weighting based on propensity scores. Read More

View Article and Full-Text PDF

The First Case Report of Preschool-Onset SS/SLE Coexisting With NMOSD of Chinese Origin.

Front Immunol 2022 2;13:887041. Epub 2022 May 2.

Department of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, China.

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease (CTD), the main features of which are multiple serum autoantibodies and extensive involvement of multiple systems. The onset age of patients varies from childhood to middle age, with nearly 1/5 in childhood. Sjogren's syndrome (SS) is also an autoimmune disease characterized by high-degree lymphocytic infiltration of exocrine glands, usually occurring in middle-aged and older women, and rarely in childhood. Read More

View Article and Full-Text PDF

Diagnostic gene biomarkers for predicting immune infiltration in endometriosis.

BMC Womens Health 2022 May 18;22(1):184. Epub 2022 May 18.

Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100026, China.

Objective: To determine the potential diagnostic markers and extent of immune cell infiltration in endometriosis (EMS).

Methods: Two published profiles (GSE7305 and GSE25628 datasets) were downloaded, and the candidate biomarkers were identified by support vector machine recursive feature elimination analysis and a Lasso regression model. The diagnostic value and expression levels of biomarkers in EMS were verified by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blotting, then further validated in the GSE5108 dataset. Read More

View Article and Full-Text PDF

Improved executive function in patients with systemic lupus erythematosus following interactive digital training.

Lupus 2022 May 18:9612033221098534. Epub 2022 May 18.

2930National Jewish Health, Denver, CO, USA.

Objective: This study aimed to evaluate the sensitivity of a digital platform to assess attentional and executive function in systemic lupus erythematosus (SLE) patients, and to evaluate the impact of an at-home interactive digital treatment to improve cognitive dysfunction in this clinical population.

Background: Deficits in attention and executive function are common in patients with SLE. Despite these cognitive difficulties, there are limited brief assessment techniques and few treatment options to improve cognitive abilities in patients with SLE. Read More

View Article and Full-Text PDF

Multidimensional immune profiling of cutaneous lupus erythematosus in vivo stratified by patient responses to antimalarials.

Arthritis Rheumatol 2022 May 18. Epub 2022 May 18.

Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104.

Objective: The pathogenesis of cutaneous lupus erythematous (CLE) is multifactorial and CLE is difficult to treat due to heterogeneity of inflammatory processes between patients. Antimalarials such as hydroxychloroquine (HCQ) and quinacrine (QC) have long been first-line systemic therapy; however, many patients do not respond and require systemic immunosuppressants with undesirable side effects. Given the complexity and unpredictable responses in CLE, we sought to identify the immunologic landscape of CLE patients stratified by subsequent treatment outcomes to identify potential biomarkers of inducible response. Read More

View Article and Full-Text PDF